Reported results
- Net sales were $874.5 million, an increase of 8.7% compared to the prior-year period.
- Diluted EPS (U.S. GAAP) was $3.02, an increase of 57.3% compared to the prior-year period.
- Adjusted-diluted EPS (non-U.S. GAAP) was $2.66, an increase of 35.7% compared to the prior-year period.
- Proprietary Products segment net sales were $728.8 million, an increase of 12.6% compared to the prior-year period.
- West Vantage segment net sales were $145.7 million, a decrease of 7.3% compared to the prior-year period.
- Reported operating profit margin (U.S. GAAP) was 30.6% for the third quarter of 2026.
Guidance
- Full-year 2026 net sales guidance is a range of $3.41 billion to $3.42 billion.
- Full-year 2026 adjusted-diluted EPS guidance is a range of $9.38 to $9.48.
- Full-year 2026 organic net sales growth guidance is a range of 11.3% to 11.6%.
- Full-year 2026 capital spending guidance is a range of $215 million to $220 million.
Notes
The company recorded a pre-tax gain of $55.7 million on the sale of its SmartDose® 3.5mL On-Body Delivery System assets in the third quarter of 2026.
Price and volatility reaction
The stock moved +3.2% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -19.2 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 403.64 | 2026-10-28 |
| Close after release | 416.67 | 2026-10-29 |
| Realised move | +3.2% | close to close |
| 30d ATM IV change | -19.2 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.
